• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Coro­n­avirus up­date: A sum­mit in Gene­va, WuXi hunts an­ti­bod­ies and J&J part­ners on a vac­cine search

6 years ago
R&D
Coronavirus

Corey Good­man mar­shals $105M mega-round for his CD47 up­start, look­ing to break new ground in PhII

6 years ago
Financing
Startups

Catch­ing up with Roche, Mer­ck racks up pos­i­tive da­ta in front­line triple neg­a­tive breast can­cer

6 years ago
R&D
Pharma

New Sanofi chief Paul Hud­son takes the ax to his ex­ec­u­tive com­mit­tee, chop­ping 4 key play­ers

6 years ago
R&D

Lil­ly, No­vo Nordisk fight in­sulin biosim­i­lars with tweaks to FDA draft guid­ance

6 years ago
Pharma
FDA+

Eas­ing con­cerns, Fi­bro­Gen, As­traZeneca se­cure FDA date for their ane­mia drug in broad chron­ic kid­ney dis­ease ...

6 years ago
R&D
FDA+

Lig­and buys its way in­to part­ner­ship with Roche, CF Foun­da­tion — plus some ion chan­nel tech once owned by Pfiz­er

6 years ago
Deals

Bay­er hands over a big drug R&D op­er­a­tion to CRO amid an on­go­ing re­struc­tur­ing ef­fort

6 years ago
Deals
R&D

A Chi­nese com­pa­ny is al­ready mass pro­duc­ing Gilead­'s ex­per­i­men­tal coro­n­avirus drug

6 years ago
China
Coronavirus

The Wuhan coro­n­avirus has an of­fi­cial name: COVID-19; Rev­o­lu­tion Med­i­cines up­sizes IPO terms

6 years ago
News Briefing
Coronavirus

Agios' Lewis Cant­ley re­turns with a new com­pa­ny and, he claims, a ma­jor on­co­log­i­cal dis­cov­ery

6 years ago
R&D

Pfiz­er un­cou­ples from Gly­coMimet­ics and its failed sick­le cell dis­ease drug

6 years ago
Deals
R&D

No­var­tis nabs pri­or­i­ty re­view for a block­buster-to-be aimed at NSCLC niche — de­light­ing In­cyte ex­ecs

6 years ago
FDA+

Up­start can­cer biotech re­cruits a top Pfiz­er on­col­o­gy re­searcher as CSO — could an IPO be far be­hind?

6 years ago
R&D

Mer­ck-al­lied Seat­tle Ge­net­ics’ pos­i­tive up­date on its 2nd ADC may point to an ac­cel­er­at­ed dash to the FDA fin­ish ...

6 years ago
R&D

Mod­er­na eyes $500M sec­ondary of­fer­ing on up­beat coro­n­avirus vac­cine up­date — al­most ready for the clin­ic

6 years ago
Deals
Coronavirus

Mer­ck walks away from KalVista, who turns their sights on HAE

6 years ago
Deals

Trump’s 2021 bud­get re­quest seeks mod­est fund­ing in­crease for FDA

6 years ago
FDA+

FDA slaps a hold on Log­icBio and its gene edit­ing plans — shares tum­ble

6 years ago
Cell/Gene Tx
FDA+

With block­buster dreams, Ex­elix­is is look­ing for some re­demp­tion for cabo in prostate can­cer. It won’t be easy

6 years ago
R&D
Pharma

Vivek Ra­maswamy's Ar­bu­tus kills an­oth­er pro­gram over safe­ty, stock takes an­oth­er hit

6 years ago
R&D

Are pri­or­i­ty re­view vouch­er pro­grams stim­u­lat­ing drug de­vel­op­ment? The da­ta sug­gest not re­al­ly, finds GAO re­port

6 years ago
R&D
FDA+

Eye drop de­vel­op­er Oculis show­cas­es pos­i­tive PhII da­ta; Aque­s­tive hunts for an­oth­er FDA OK

6 years ago
News Briefing

Sci­ence team de­signs a new CAR they say may work much bet­ter than BC­MAs in fight­ing mul­ti­ple myelo­ma

6 years ago
R&D
First page Previous page 858859860861862863864 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times